Finally, in vivo testing against TRBC1 and TRBC2 expressing T cell lines in NSG mice (HPB-ALL endogenous TRBC2, Jurkat endogenous TRBC1, and Jurkat engineered TRBC2) showed selective tumor growth control by HuJovi-1 CD8Stk-TyrpTM-CD28z and KFN CD28Stk-CD28TM-CD28z CAR T cells, respectively, without affecting the non-target tumor cells. Here, TRBC1 is linked to neoplasm.